Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

Haematologica

Volumn 95, Issue 3, 2010, Pages 518-519

  Flach, Johanna ^a   Dicker, Frank ^a   Schnittger, Susanne ^a   Kohlmann, Alexander ^a   Haferlach, Torsten ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

JAK2; RARS T; TET2 mutations; WHO classification

Indexed keywords

CBL PROTEIN; JANUS KINASE 2; MOLECULAR MARKER; PROTEIN TET2; UNCLASSIFIED DRUG;

CHROMOSOME 1P; CHROMOSOME 4; CHROMOSOME 9P; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME LOSS; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; GENE LOCUS; GENETIC MARKER; HUMAN; LETTER; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOSIS; UNIPARENTAL DISOMY;

AGED; AGED, 80 AND OVER; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-CBL; THROMBOCYTOSIS;

EID: 77949732119     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013631     Document Type: Letter

References (12)

1. th, 2008. Lyon, International Agency for Research on Cancer (IARC).
2. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006; 108(7):2173-81.
3. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009; 113(24):6182-92.
4. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia. 2009;23:(3):610-4.
5. Mullighan CG. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet. 2009;41(7):766-7.
6. Mohamedali AM, Smith AE, Gaken J, Lea NC, Mian SA, Westwood NB, et al. Novel TET2 mutations associated with UPD4q24 in myelodysplastic syndrome. J Clin Oncol 2009; 27(24):4002-6.
7. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet. 2009;41(7):838-42.
8. Delhommeau F, Dupont S, Della V, James C, Trannoy S, Masse A, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-301.
9. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009;23(7):1343-5.
10. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood. 2009;113(25):6403-10.
11. Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008;93(1):34-40.
12. Malcovati L, della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-45.